FY2028 Earnings Estimate for AUTL Issued By William Blair

Autolus Therapeutics plc (NASDAQ:AUTL) – Equities researchers at William Blair issued their FY2028 earnings per share (EPS) estimates for Autolus Therapeutics in a research report issued on Thursday, March 20th. William Blair analyst M. Phipps expects that the company will post earnings of ($0.18) per share for the year. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share.

A number of other research analysts have also recently issued reports on the company. Wells Fargo & Company reduced their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research note on Friday. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, January 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $9.52.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $1.71 on Monday. Autolus Therapeutics has a fifty-two week low of $1.56 and a fifty-two week high of $6.60. The firm has a 50 day moving average price of $2.01 and a 200-day moving average price of $2.88. The firm has a market cap of $455.02 million, a price-to-earnings ratio of -1.41 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $2.98 million.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtus ETF Advisers LLC increased its stake in Autolus Therapeutics by 29.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock valued at $62,000 after purchasing an additional 6,081 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in Autolus Therapeutics by 55.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock worth $56,000 after purchasing an additional 8,479 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after buying an additional 9,000 shares during the period. State Street Corp grew its holdings in shares of Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after acquiring an additional 10,401 shares during the period. Finally, Barclays PLC lifted its holdings in Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after acquiring an additional 10,866 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.